EUCTR2006-000868-83-GB进行中（未招募）不适用
A Phase I/II Study of CP-4055 in Patients with Refractory/Relapsed Hematologic Malignancies
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients with a confirmed diagnosis of AML according to WHO classification (excluding acute promyelocytic leukemia) who have received at least two previous regimens of chemotherapy and
- •A. have never achieved CR or CRp, or
- •B. have relapsed after a CR1 or CRp and failed to respond to a cytotoxic first salvage therapy, or have relapsed after = 6 months from a CR2 or CRp
- •2. Patients must be 18 years of age or older
- •3. Patients must have ECOG performance status (PS) of 0 – 2.
- •4. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to beginning treatment on this study. Nursing patients are excluded.
- •Male and female patients must use acceptable contraceptive methods for the duration of time on study, and males also for 3 months after the last CP-4055 dose
- •5. Patients must be capable of understanding and complying with parameters as outlined in the protocol, and able and willing to sign a written informed consent form
- •6. In the absence of rapidly progressing disease, the interval from prior treatment to time of study drug administration should be at least 2 weeks for cytotoxic agents, or at least 5 half-lives for noncytotoxic agents
- •If the patient is on hydroxyurea to control peripheral blood leukemic cell counts, the patient must be off hydroxyurea for at least 24 hours before initiation of treatment on this protocol. Persistent chronic clinically significant toxicities from prior chemotherapy must not be greater than Grade 1
- •7. Patients must have the following clinical laboratory values:
- •Serum creatinine = 1.5 x the institutional upper limit of normal (ULN)
- •Total bilirubin = 1.5 x the ULN unless considered due to Gilbert’s syndrome
- •Alanine aminotransferase (ALT) (SGPT), or aspartate aminotransferase (AST) (SGOT) = 2.5 x the ULN unless considered due to organ leukemic involvement.
- •8. Patient’s bone marrow aspirates and/or biopsies must contain > 5 % blasts or patient must have biopsy-proven extramedullary AML, or patient’s peripheral blood shows occurrence of leukemic blasts
- •9. Previous bone marrow and/or stem cell transplantation must be completed a minimum of 3 months prior to inclusion in the study. Allogenic transplanted patients must be off immunosuppressive treatment for a minimum of 4 weeks. There is no restriction on number of regimens or type of treatment administered for maintenance or consolidation in CR1 or CR2 or CRp.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. A history of allergic reactions to egg
- •A history of allergic reactions of CTCAE grade 3 or 4 to ara-C
- •2. Known CNS leukemia
- •3. Another known active cancer within the last 5 years
- •4. Known positive status for human immunodeficiency virus (HIV) or hepatitis B or C
- •5. Pregnant and nursing patients are excluded because the effects of CP-4055 on a fetus or nursing child are unknown
- •6. Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •7. Active heart disease including myocardial infarction within previous 3 months, symptomatic coronary artery disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure. Any NYHA grade 3 or 4.
- •8. Patients receiving any other standard or investigational cytotoxic treatment for their hematologic malignancy
- •9. Any medical condition which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities.
研究者
相似试验
进行中（未招募）
不适用
A Phase I/II Study of CP-4055 in Patients with Refractory/Relapsed Hematologic MalignanciesEUCTR2006-000868-83-DEClavis Pharma ASA200
进行中（未招募）
不适用
A phase II Clinical Study of CP-4055 in patients with metastatic melanoma not previous treated with chemotherapy - CP4055-201A phase II clinical study of CP-4055 in patients with metastatic melanoma not previous treated with chemotherapyEUCTR2005-000690-22-SEClavis Pharma as42
进行中（未招募）
不适用
A Phase I/II Study of CP-4055 in Patients with Platinum Resistant Ovarian Cancer - CP4055-204EUCTR2007-003323-20-BEClavis Pharma ASA50
进行中（未招募）
1 期
A phase II Clinical Study of CP-4055 as second line therapy in patients with advanced colorectal cancer - CP4055-202A phase II clinical study of ELACYT as second line therapy in patients with advanced colorectal cancerEUCTR2006-006766-41-GBClavis Pharma ASA42
进行中（未招募）
1 期
A phase II study of CP-751,871 in patients with recurrent and/or metastatic squamous head and neck carcinoma - IGF-1R protocolEUCTR2008-004707-59-FRCliniques Universitaires Saint Luc-Centre du Cancer